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ABSTRACT 
 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not 
intranasal ketorolac is both safe and effective in reducing acute postoperative pain for patients 
over 18 years of age that require inpatient hospitalization.  
 
STUDY DESIGN: Review of three double-blind randomized controlled trials (RCTs) were used, 
all are from 2008 to present and all are in the English language.  
 
DATA SOURCES: Data sources include articles that were published on both PubMed and 
Cochrane databases and were selected based on their relevance to the research question as well 
as patient measured outcomes. 
 
OUTCOMES MEASURED: Outcomes measured include efficacy of the drug measured through 
Visual Analog Scale (VAS), Pain Intensity Differences (PID) and Summed Pain Intensity 
Differences at 6 hours (SPID6) as well as safety measured through self-reported adverse events 
or change in clinical status. 
 
RESULTS: The study by Moodie et al.6 showed a significant increase of 64.9 (p=0.0015) in 
SPID6 scores between intranasal ketorolac and placebo. Brown et al.7 also showed a significant 
increase of 46.1 (p=0.007) in the SPID6 scores between the groups. Finally, Singla et al.8 
additionally demonstrated a significant increase of 27.6 (p=0.03) in SPID6 scores between the 
two groups.  
 
CONCLUSIONS: All three studies demonstrated that intranasal ketorolac is both safe and 
effective in reducing pain postoperatively.  
 
KEY WORDS: Intranasal ketorolac; postoperative pain 
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INTRODUCTION 
 Postoperative pain is one of the most common side effects that follows a surgical 
procedure and can also be one of the most challenging to manage. As many as 80% of patients 
admit to acute pain after surgery but under 50% report sufficient pain control before and after 
discharge.1 Long term consequences of inadequately controlled pain can include increased post-
surgical complications, decreased quality of life and persistent chronic pain.1 The estimated 
economic burden of pain cost the United States between $560-$665 billion, including lost 
productivity and healthcare costs, which was reported in 2010.2 The exact number of healthcare 
visits per year is unknown, however, about 10.3 million inpatient surgeries were performed in 
2014 so an estimated 8.2 million stays per year would have required post-operative pain 
management.3 
 Pain is a broad definition that describes the body’s physiological response to nerve 
stimulation or tissue damage and involves both physical and emotional responses from the body.4 
Although the pain pathway is quite complex, tissue damage from injury or surgery triggers 
nociceptors in the nerve endings to send electrical signals to the brain. These electrical signals 
are received to the brain on varying intensities based on their threat to the tissue.4 The brain will 
then send adaptive responses to the tissue, such as reflex mechanisms and/or inflammatory 
mediators, to prevent further injury and start repairing the damage. Acute pain occurs from some 
known direct insult to the body, such as an injury or surgical procedure.4 Chronic pain occurs 
over months or even years at a time and can occur from improperly controlled acute pain even 
once the original injury has healed.4 Each individual experiences and perceives pain differently 
and can lead to various challenges when properly treating and managing acute pain 
postoperatively.  
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 Adequately controlling acute pain postoperatively through analgesic therapy is key in 
order to prevent stressful physiologic responses and adverse health consequences. For example, 
if patients are in too much pain to get out of bed and ambulate after surgery, they are at a 
significantly higher risk for acquiring complications such as blood clots, pneumonia, atelectasis, 
etc.5 The mainstay of treatment for postoperative pain is opioid analgesics; this can be given 
intravenously (IV), such as through patient-controlled analgesic (PCA) pumps, or given orally.5  
Some of the most common opioid analgesics used are morphine, fentanyl, hydromorphone, and 
hydrocodone.5 Other nonnarcotic oral or IV drugs given alone or in combination with opioids to 
control pain include acetaminophen, non-steroidal anti-inflammatory drugs (NSAIDS), and/or 
gabapentin.5 Epidural or peripheral nerve infusion can also be given to control pain for certain 
procedures that involve larger areas of nerve involvement, such as abdominal procedures.5  
 Practitioners must be mindful when prescribing narcotic medications due to the 
possibility of over-sedating their patients, which can lead to potentially fatal side effects such as 
respiratory depression and apnea.5 Opioid medications are also highly addictive leading to 
regulation and hesitation by health care providers when prescribing narcotic medication, 
especially long term. Ketorolac is a non-steroidal anti-inflammatory medication that has been 
proven to provide potent analgesic effects, similar to morphine, to control moderate to severe 
pain after surgery.6,7,8 The intranasal (IN) route provides additional benefits since it is quickly 
absorbed into the bloodstream but does not require an intravenous line to be administered.6,7,8  
OBJECTIVE 
 The objective of this selective EBM review is to determine whether or not intranasal (IN) 
ketorolac is both safe and effective in reducing acute postoperative pain for patients over 18 
years of age that require inpatient hospitalization.  
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METHODS 
 The studies selected for this EBM review were found using PubMed and Cochrane 
Library databases to incorporate three placebo-controlled, double-blind RCTs that included 
adults over the age of 18 that were undergoing surgery with inpatient postoperative care. The 
intervention being observed in each study was intranasal ketorolac; Moodie et al.6 and Brown et 
al.7 used 30 mg of IN ketorolac in a 100 µL solution while Singla et al.8 used 31.5 mg of IN 
ketorolac in a 100 µL solution. All studies were compared to a matched placebo that was similar 
in container shape, medication color, and administration. Patients still had access to morphine for 
pain and could receive back-up pain medication if study drug was not adequate for pain control. 
Outcomes measured in these studies was efficacy in pain reduction through summed pain 
intensity differences at 6 hours (SPID6) taken through patient reported visual analog scales 
(VAS) for pain and pain intensity differences (PID) as well as safety through reports of adverse 
events or change in clinical state. 
 All three RCTs were found in peer-reviewed journals and were published in English 
during or after 2007.  Articles were then selected based on relevance to the clinical question and 
if their results focused on patient-oriented outcomes (POEMS). Inclusion and exclusion criteria 
for this review were applied to all three articles. Inclusion criteria were adults over 18 years of 
age that underwent an inpatient surgical procedure that required subsequent inpatient care and 
pain management. Exclusion criteria included subjects under 18 years of age and studies that 
comprised of other treatment modalities other than standard of care compared to the study drug. 
Table 1 demonstrates all specific inclusion and exclusion criteria for each study. Values reported 
for pain reduction were given in p-values in all three studies while a CI was given for Singla et 
al.8 and safety was reported by calculating number needed to harm (NNH) for each study. 
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Table 1. Demographics & Characteristics of included studies  
Study Typ
e 
# 
Pts 
Age Inclusion 
Criteria 
Exclusion Criteria W/D Interventions 
Moodie6 
(2008) 
RCT 84 > 18 
years 
of age 
(mea
n age 
53) 
-Over 18 years old 
and weighing 
between 100 to 
300 pounds 
-Pain intensity 
score >40 mm out 
of 100mm (VAS 
scale) 
-expected 
inpatient stay over 
48 hours 
-Negative 
Pregnancy Test 
-Willingness to 
comply and 
complete 
posttreatment visit 
-Allergy, sensitivity or 
contraindication (CI) 
to the use of NSAIDS 
(active bleeding/PUD, 
renal impairment, etc.) 
-Use of any IN 
product w/in 24 hours  
-Current URI, past or 
present cocaine use, or 
other respiratory tract 
condition or 
abnormality that 
would interfere with 
medication absorption 
or reporting adverse 
events 
-Clinically significant 
abnormality on 
screening test (w/in 
one month) 
-Pregnancy or 
breastfeeding 
17 30-mg IN 
ketorolac 
given to 
subjects 
every 8 hours 
through 40 
hours 
 
Brown7 
(2009) 
RCT 300 Rang
e of 
19- 
81 
years 
old 
(mea
n age 
52) 
- Over 18 years of 
age undergoing 
major surgery and 
expected to stay in 
the hospital for at 
least 48 hours and 
up to 5 days 
-Allergy, sensitivity, 
or CI to NSAIDs or 
opiate analgesics 
-GI bleeding disorder 
-Current URI or other 
conditions that 
interferes with 
intranasal absorption  
-Use of other IN 
products w/in 24 hours  
-Pregnancy or 
breastfeeding 
90 30-mg IN 
ketorolac 
administered 
three times 
daily for up 
to 5 days 
Singla8 
(2010) 
RCT 321 Rang
e of 
18-64 
years 
old 
(Mea
n age 
46) 
-Ages 18-64 
undergoing major 
abdominal surgery 
(US and New 
Zealand) under 
general analgesia 
expected to remain 
in the hospital for 
at least 48 hours 
and up to 5 days  
-Recent or current 
PUD/GI bleeding 
-Allergies, sensitivities 
or CI to study drugs 
-Current URI that 
could interfere with 
drug absorption  
-Use of any other IN 
product w/in 24 hours  
-Pregnancy or 
breastfeeding 
20 31.5-mg IN 
ketorolac 
given every 6 
hours for the 
first 48 hours 
and then up 
to 4 times per 
day 
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OUTCOMES MEASURED 
Outcomes measured in all three studies were pain reduction through the VAS, PID and 
SPID6 scores while also measuring safety through adverse events (AE). All studies had patients 
rate their pain on the VAS with “0” being absolutely no pain and “100” being worst pain 
imaginable. Treatment began when their first VAS was greater than or equal to 40 and measured 
again at certain time intervals, usually at 30 minutes and then hourly, for a minimum of 6 hours 
and up to 2 to 5 days (as needed). The PIDs were then calculated by taking their baseline score 
and subtracting their pain score at certain time intervals after the drug was administered. All 
weighted PID scores were then analyzed to get the SPID6 results which is a sum of all PID 
scores for the first 6 hours. Greater difference in the SPID6 values between IN ketorolac and the 
placebo indicates a greater treatment effect. Safety was measured through adverse events 
reported by the patients or by change in clinical status (such as vitals, appearance, etc.) and then 
measured through NNH. 
RESULTS 
 Three double-blind, placebo-controlled RCTs were evaluated to assess if intranasal 
ketorolac is both safe and effective for reducing postoperative pain in patients over 18 years of 
age that require inpatient hospitalization. Moodie et al.6 and Brown et al.7 measured 30 mg of IN 
ketorolac and Singla et al.8 measured 31.5 mg of IN ketorolac, all to a matched placebo. All 
studies also measured adverse events in both groups. Table 1 above provides all inclusion and 
exclusion criteria. 
 In Moodie et al.6 study, 84 subjects were enrolled to either receive placebo or 30 mg IN 
ketorolac.6 Baseline characteristics were marginally similar, however, there was a slight trend 
toward older, white men in the placebo group compared to the experimental.6 The intervention 
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for the experimental group was 30 mg of IN ketorolac (2 x 100 µL of 15% solution).6 Both the 
experimental drug and matched placebo were given in an IN metered device to administer 100 
µL of aerosolized medication per nostril.6 Nurses on the post-surgical units would educate 
patients on correct administration so that they were able to self-administer throughout the study.  
General anesthesia was given to all patients prior to and during surgery. All patients had access 
to a PCA morphine pumps and rescue opioid medications for pain after surgery though no 
subjects requested rescue medications. VAS and PID scores were calculated at multiple time 
intervals for two days, but for the purpose of this analysis, only the first 6 hours were included 
(at 30 minutes and then 1,2,3,4,5, & 6 hours).6 SPID6 results were analyzed with the Kruskal-
Wallis test between the two groups.6  The SPID6 score for the experimental group was 195.5 
while the SPID6 score for the placebo group was 130.6 with a difference in SPID6 scores of 64.9 
(p= 0.0015).6 Table 2 has a summary of the results below. Safety was also assessed by total 
adverse events (AE) and calculating the NNH. AE were compared upon both treatment groups 
using the chi-square (χ2) test or Fisher’s exact test, as applicable.6 The IN ketorolac group had a 
AE frequency rate of 95.2% while the placebo group has a AE frequency rate of 97.6%.6 Nausea 
and pyrexia were the most common AE overall but there was a 28.6% decrease of pyrexia in the 
ketorolac group compared to placebo.6 Nasal passage irritation was one of the only AE much 
higher in the ketorolac group (16.7%) compared to placebo (11.9%).6 The NNH was calculated 
at -50 which means that 1 less patient will experience an adverse event with IN ketorolac 
compared to the placebo for every 50 patients treated. Table 3 has the results below. 
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Table 2: Mean Baseline VAS Scores and Difference in SPID6 Values 
 Mean Baseline 
VAS Score (SEM) 
SPID6 Values 
(SEM) 
Difference between 
SPID6 Values 
P-Value 
Experimental 
Group 
52.0 (1.5) 195.5 (12.1)  
64.9 
 
P=0.0015 
Control Group 51.4 (1.7) 130.6 (14.4) 
 
Table 3: Comparison of Occurrences in Adverse Events between Ketorolac and Placebo 
Control event 
rate (CER) 
Experiment 
event rate (EER) 
Relative risk 
increase (RRI) 
Absolute risk 
increase (ARI) 
Number needed 
to harm (NNH) 
0.976 0.952 -0.025 -0.024 -50 
 
 In Brown et al.7 study, 300 patients were initially enrolled in the study in a 2:1 ratio 
(ketorolac to placebo, respectively) but only 210 patients (133/199 in the ketorolac group and 
72/101 in the placebo group) completed all 5 days of dosing.7 Most common reasons for 
withdrawal were adverse events, concurrent illness and/or lab abnormality (33/199 in ketorolac 
group and 14/101 in placebo group).7 A last observation carried forward approach was taken for 
the subjects who withdrew early.7 Demographics and vital signs were similar between both 
groups. Most patients were middle-aged white women undergoing a total hysterectomy or hip 
replacement, though other invasive surgical procedures were included.7 The experimental group 
intervention was 30 mg of IN ketorolac (100 µL solution) administered in a meter-pumped spray 
delivery system with one spray per nostril.7 The placebo drug was similar in all aspects except 
containing the active drug, ketorolac. Study nurses would educate patients on correct 
administration so that they were able to self-administer throughout the study when comfortable 
to do so. Participants had access to a morphine PCA pump and backup analgesics in this study 
while some partook in a single-dose trial without backup analgesics, however, this was not 
evaluated in this analysis. The PID ratings were analyzed with one-way analysis of variance 
(ANOVA) while the treatment group differences were analyzed with log-rank test.7 PID and 
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SPID6 scores were analyzed using analysis of covariance with baseline PI scores.7 The SPID6 
scores for the experimental group was 83.3 (+/- 10.6) while the SPID6 scores for the placebo 
group was 37.2 (+/-12.9) with a difference of 46.1 (p=0.007).7 Table 4 has data summarized 
below. Safety was assessed similarly to the study above through reported AE or change in 
clinical status. P-values used to determine differences in AE between the two groups were 
calculated with χ2 test.7 The IN ketorolac group had a AE frequency rate of 97.5% while the 
placebo group has a AE frequency rate of 98%.7 Nasal irritation, throat irritation, and lacrimation 
were higher in the ketorolac group compared to placebo, but pyrexia/intermittent pyrexia and 
pruritis were reduced in the ketorolac group compared to placebo.7 Most adverse events were 
either mild or moderate in nature. NNH was calculated with a result of -200. Table 5 has 
summary of results below. 
Table 4: Mean Baseline VAS Scores and Difference in SPID6 Values 
 Mean Baseline 
VAS Score (SEM) 
SPID6 Values 
(SEM) 
Difference between 
SPID6 Values 
P-Value 
Experimental 
Group 
54.7 (+/- 0.6) 83.3 (+/- 10.6)  
46.1 
 
p=0.007 
Control Group 54.1 (+/- 0.9) 37.2 (+/-12.9) 
 
Table 5: Comparison of Occurrences in Adverse Events between Ketorolac and Placebo 
Control event 
rate (CER) 
Experiment 
event rate (EER) 
Relative risk 
increase (RRI) 
Absolute risk 
increase (ARI) 
Number needed 
to harm (NNH) 
0.98 0.975 -0.005 -0.005 -200 
 
 In Singla et al.8 study, a total of 321 patients were enrolled in the study and grouped in a 
2:1 ratio (ketorolac to placebo, respectively).8 301 patients completed the 2-week follow up at 
the termination of the study; 203 patients in the experimental group (95%) and 98 patients in the 
placebo group (92%).8 A last observation carried forward approach was taken for the subjects 
who withdrew early.8 Demographic differences between the two groups were similar and most 
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patients were white, middle-age females undergoing partial or total hysterectomies.8 The 
experimental drug contained 31.5 mg of ketorolac in a 15% solution.8 The matched placebo was 
contained in an identical meter-pumped container and both groups were administered 100 µL of 
solution to each nostril. Subjects were given a kit containing five devices, each containing a 
month’s supply of the study drug. All patients had access to a PCA morphine pump for the first 
48 hours and then rescue opioid medications as needed. VAS and PID scores were assessed at 
multiple time intervals, but only those taken at 20,40, and 60 minutes, and 2,3,4,5, and 6 hours 
after the first dose will be used for this analysis.8 PID and SPID scores were analyzed using the 
two-way analysis of covariance with the baseline PI score made prior to study as covariate.8 The 
SPID6 scores for the experimental group was 117.4 (+/- 7.7) while the SPID6 scores for the 
control group was 89.9 (+/- 10.6).8 The difference between the scores was 27.6 (p=0.032 with 
95% CI 2.5-52.7).8  Table 6 has a summary of the data below. Safety was also measured through 
AE and calculating NNH. The IN ketorolac group had a AE frequency rate of 93% while the 
placebo group has a AE frequency rate of 96%.8 Nausea, constipation and vomiting were the 
most reported AE between both groups.8 Nasal discomfort, rhinalgia and anemia occurred more 
frequently in the ketorolac group compared to placebo, however, there were less incidences of 
nausea, constipation, pyrexia and tachycardia in the ketorolac group compared to placebo.8 The 
NNH was calculated at -33. Table 7 summarizes results for safety below.   
Table 6: Mean Baseline VAS Scores and Difference in SPID6 Values 
 Mean Baseline 
VAS Score (SEM) 
SPID6 Values 
(SEM) 
Difference between 
SPID6 Values 
P-Value and 
CI 
Experimental 
Group 
62.5 (+/- 1.6) 117.4 (+/- 7.7)  
27.6 
p=0.032 with 
95% CI 2.5-
52.7 Control Group 60.8 (+/- 1.1) 89.9 (+/-10.6) 
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Table 7: Comparison of Occurrences in Adverse Events between Ketorolac and Placebo 
Control event 
rate (CER) 
Experiment 
event rate (EER) 
Relative risk 
increase (RRI) 
Absolute risk 
increase (ARI) 
Number needed 
to harm (NNH) 
0.96 0.93 -0.031 -0.03 -33 
 
DISCUSSION 
 Ketorolac is an accepted adjunctive therapy for acute post-surgical pain management in 
adults over 18 years of age. Although opioid medications continue to be first line as stated above, 
using multiple modalities of medication may better treat acute postoperative pain to reduce side 
effects and decreased quality of life. The IN route allows for easy and quick absorption which 
allows patients to administer the medication without the need for an IV catheter.6,7,8 Although 
ketorolac is an effective analgesic component for post-surgical treatment, it is not indicated for 
all populations. All NSAIDs pose an additional risk to those who have current/past peptic ulcer 
disease or gastric bleeding, those at higher risk for cardiovascular thrombosis events, and those 
who have decreased or worsening kidney functions.9 Ketorolac is only indicated for maximum 5 
days of use in adults and should not be used in chronic pain management.9 
 All three studies showed a significant pain improvement between the experimental and 
control groups (p < 0.05). This could potentially mean that patients who are eligible for ketorolac 
could have a significant decrease in pain following a surgical procedure. Benefits of controlling 
pain more adequately after a procedure could include shorter hospital stays, decreased sequala, 
return to baseline more quickly and less incidences of chronic pain.1,5 Although these studies 
focused on inpatient research, limited research is currently available on the use of IN ketorolac in 
the outpatient surgical setting. Upon original research for this analysis, only one RCT was found 
and this study demonstrated that IN ketorolac was effective in reducing postoperative pain in 
patients undergoing outpatient dental procedures.10  
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 The main limitation to all studies, which may have affected the outcome or limited the 
applicability of the results, is the demographics of the study populations. All three studies used in 
this analysis primarily included white, middle-aged women undergoing hysterectomies. The 
sample size from each study was adequate but may have been too inclusive to a certain 
population for the results to be relevant for all surgical patients.  Other surgical modalities and 
varying demographics were included in each study but not to the same proportion. Additionally, 
Moodie et al.6 and Brown et al.7 had a large loss to follow-up (>20%) which could also alter the 
impact of the results since the drug may have been given but the research team was unable to 
account for the effects and had to accept their last scores taken before withdrawing. 
CONCLUSION 
 The clinical trials included in the analysis demonstrated that IN ketorolac is both 
relatively effective and safe in treating acute postoperative pain in a small group of patients over 
18 years old. All three studies showed that pain was both better controlled and produced similar 
occurrences or even a reduction in AE with IN ketorolac compared to placebo. Further studies 
are needed in order to determine if the results carry over to a larger population size that includes 
a variety of demographics and/or more common surgical procedures. Further studies are also 
warranted to see if IN ketorolac could be applied to an outpatient surgical setting for acute 
postoperative pain. Initiating further research to address both limitations could help generalize 
the results and help normalize IN ketorolac in general practice so that practitioners could 
potentially reduce the massive burden of pain, both physically and financially, on the healthcare 
system. 
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